



# Sex and age differences in HCV notification trends

Kwon JA, Dore GJ, Grebely J, Hajarizadeh B, King J, McGregor S, Guy R, Gray RT Kirby Institute, UNSW Sydney, Sydney, New South Wales 2052, Australia

#### Introduction

- In March 2016, subsidised direct-acting antiviral (DAA) treatment became available in Australia for all adults living with HCV.
- 100,680 people initiated DAA treatment between 2016-2022 (~60% coverage).
- As a result, there has been an estimated > 50% reduction in people living with hepatitis C in 2022, compared to 2015 (prevalence).
- The impact of DAA scale-up on HCV incidence, including among males and females, is less well understood.
- HCV notification trends can provide insight into the epidemic's trajectory, with trends among younger ages (15-24-year-olds) a proxy for incidence.

### Aims

- Assess HCV notification (primary diagnoses) trends in Australia from 2009-2023.
- Assess the age and gender differences in HCV notification trends to infer potential changes in the HCV incidence during the DAA era and COVID-19 pandemic.

## Methods

- Analyzed monthly HCV notification data from January 2009 to December 2023.
- Examined trends in total and younger age (15-24 years) notifications, including by gender.
- Younger age (15-24 years old) HCV notifications were used, given likelihood they reflect more recent HCV transmission.
- Identified change points in trends using Poisson Segmented regression and assessed goodness-offit using standard statistical methods.
- Determined the best number of turning points with the lowest Bayesian Information Criteria (BIC) and reported trends with a rate ratio (RR).
- Evaluated the sensitivity of detected change points to outliers and the period of analysis.


#### Results

Figure 1: Monthly HCV notifications (primary diagnoses) during 2009-2023

A) Total national notifications; B) National notifications in 15-24-year-olds; C)

HCV notification trends among younger males (15-24 years); D) HCV

notification trends among younger females (15-24 years)



**Note: black points**: HCV notification data from NNDSS; **red line**: segmented regression trend; **vertical black-dotted line**: subsidised DAA became available (1st March 2016); **vertical red-dotted line**: year of change points

Table 1: Month change in trends occur and the rate ratio (RR) of HCV notifications before and after each changepoint

	RR	Change year 1	RR	Change year 2	RR	Change year 3	RR
National	0.99	September 2015	1.65	March 2016	0.90	February 2022	1.07
National (15-24 yrs)	1.01	June 2016	0.93	July 2022	1.11	_	_
Male (15-24 yrs)	1.06	July 2013	0.98	December 2019	0.88	May 2022	1.16
Female (15-24 yrs)	0.97	February 2017	0.93	_	-	-	_

# Conclusion<u>s</u>

- The rapid increase in HCV notifications in early to mid-2016 is likely due to increased testing associated with unrestricted DAA therapy access in March 2016.
- An increase in HCV notifications among the younger male population was observed after May 2022, contributing to an increase in overall HCV notifications.
- This could reflect either an increase in HCV incidence among males or increased HCV screening, possibly due to enhanced testing programs in prison-based settings.
- Further investigation is required to comprehend the mechanisms behind these diverging notification trends among young males and inform potential strategies for reducing increases in incidence.